Halozyme Reports First Patient Dosing In Phase 1 Clinical

Halozyme has reported first patient dosing in a phase 1 pharmacokinetic clinical trial using Enhanze Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.

Reportedly, this biologic represents the third Roche proprietary compound directed to an exclusive target to enter the clinic as part of the Halozyme Roche collaboration. Initiation of the clinical trial has triggered a milestone payment under the agreement.

Jonathan Lim, president and CEO at Halozyme, said: “The initiation of the third phase 1 clinical trial by Roche since December 2008 utilising our rHuPH20 enzyme further underscores their commitment and belief in the commercial potential of Halozyme’s technology.”